<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0EB2ECE2-59F9-4A04-B774-3F3EFD049686"><gtr:id>0EB2ECE2-59F9-4A04-B774-3F3EFD049686</gtr:id><gtr:name>Icahn School of Medicine at Mount Sinai</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0EB2ECE2-59F9-4A04-B774-3F3EFD049686"><gtr:id>0EB2ECE2-59F9-4A04-B774-3F3EFD049686</gtr:id><gtr:name>Icahn School of Medicine at Mount Sinai</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E8CA499A-8753-4884-A92A-5C8B805FD2D0"><gtr:id>E8CA499A-8753-4884-A92A-5C8B805FD2D0</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:surname>Piper Hanley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ003352%2F1"><gtr:id>368E1E0B-4366-4D5C-B586-B92B4EEDD474</gtr:id><gtr:title>Investigating the role of SOX9 in liver fibrosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J003352/1</gtr:grantReference><gtr:abstractText>Liver fibrosis is a devastating scarring reaction that results from injury to the liver (e.g. by alcohol or infection). The scarring impairs liver function. The ultimate treatment of liver fibrosis is transplantation. Unfortunately this is limited due to the high numbers of people in need of a transplant. For this reason, identifying effective anti-fibrotic treatments at early stages of disease would be hugely beneficial. To achieve this better understanding of how the scar forms is needed. Although progress has been made in this area, unfortunately there are still no approved anti fibrotic treatments. To tackle this problem, I have identified SOX9 as a core factor responsible for mediating large components of scar formation. It is now essential to determine whether loss of SOX9 can be used as a means of reversing scar formation and ultimately fibrosis in the liver. This project will develop models to test whether loss of Sox9 prevents or ameliorates liver fibrosis and if over-expression of Sox9 worsens or accelerates the disease. In addition, I will discover what other genes lie downstream of SOX9 and integrate these with known signalling pathways important in liver fibrosis to uncover new targets and potential for therapies against liver fibrosis.
Taken together, these experiments are anticipated to prove an important role for Sox9 in organ fibrosis and assist in identifying new pathways of value in the search for new therapies.</gtr:abstractText><gtr:technicalSummary>Fibrosis of the liver is characterised by progressive accumulation of ECM proteins and is a major cause of morbidity and mortality in the UK. End-stage liver fibrosis can be treated by liver transplantation, but this is limited by donor numbers. Anti-fibrotic therapies are desperately needed during earlier phases of the disease when the fibrosis is reversible. To achieve this, better mechanistic understanding of liver fibrosis is required. Despite progress in this area, there are still no approved anti fibrotic treatments. To tackle this problem, identifying core factors and their mechanism of action will be highly influential; SOX9 represents one of these factors. 
A series of data implicate ectopic expression of the Sry-box transcription factor, SOX9, as important in vitro in hepatic stellate cells and their deposition of extracellular matrix (ECM) characteristic of liver fibrosis. Two pressing challenges are now to test these data in vivo to determine if loss of Sox9 prevents or ameliorates liver fibrosis and if over-expression of Sox9 worsens or accelerates the disease; and to determine the genomic-wide binding of Sox9 to help identify direct genetic targets of Sox9 action and to elucidate the downstream pathways that may facilitate novel therapeutic intervention. 
Taken together, these experiments are anticipated to prove an important role for Sox9 in organ fibrosis and assist in identifying new pathways of value in the search for new therapies.</gtr:technicalSummary><gtr:potentialImpactText>Liver fibrosis is increasing in incidence and is a major cost to the NHS. It is associated with major morbidity and mortality. Largely, this problem comes from the lack of effective therapies at stages of the disease where the damage is reversible. This makes transplantation the last option and only then for lucky individuals where a donor organ is available. This research project will discover whether loss of the transcription factor SOX9 can ameliorate or reverse fibrosis. It will discover new genes involved in liver fibrosis as downstream targets of SOX9 action and it will place SOX9 in the context of known signalling pathways. All of these steps will increase the likelihood of identifying new candidates for targeted drug development to treat liver fibrosis prior to end-stage disease. Therefore, this work carries substantial health and wealth implications.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>453426</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Newcastle Biomedicine</gtr:department><gtr:description>University of Newcastle collaboration</gtr:description><gtr:id>30106140-F2CB-4F8B-85B8-037DCBB7AED4</gtr:id><gtr:impact>PMID: 22488688
PMID: 18296708

collaboration had led to my MRC NIRG and two MRC clinical training fellows in my lab.</gtr:impact><gtr:outcomeId>J2SprBDKEKB-1</gtr:outcomeId><gtr:partnerContribution>Tissue and methodology.</gtr:partnerContribution><gtr:piContribution>Publications in JBC and Hepatology.

Successful MRC project funding / MRC clinical training fellows.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Fibrotic mechanisms - Edinburgh</gtr:description><gtr:id>2CDDE77A-07EA-492E-BB35-42A6AC590175</gtr:id><gtr:impact>Manuscript in preparation.
Grant planning for clinical fellow (application Autumn 2015)</gtr:impact><gtr:outcomeId>54648b5097cfb0.50705877-1</gtr:outcomeId><gtr:partnerContribution>Material distribution.</gtr:partnerContribution><gtr:piContribution>Intellectual ideas and research planning.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Icahn School of Medicine at Mount Sinai</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Mount Sinai Collaboration</gtr:description><gtr:id>96AF4150-0B7E-4AF9-AF6E-268E9AB2C952</gtr:id><gtr:impact>MRC NIRG award

BRC laboratory placement</gtr:impact><gtr:outcomeId>nN49cshGt33-1</gtr:outcomeId><gtr:partnerContribution>4 months laboratory placement and techniques for postdoctoral fellow.</gtr:partnerContribution><gtr:piContribution>MRC NIRG award

BRC laboratory placement</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust</gtr:department><gtr:description>Biomarkers</gtr:description><gtr:id>568BB4F8-AA57-481E-A5FE-67E77292F2E9</gtr:id><gtr:impact>PMID: 22488688

MRC clinical training fellow</gtr:impact><gtr:outcomeId>WbUnfWPALy6-1</gtr:outcomeId><gtr:partnerContribution>Human biopsy and serum samples</gtr:partnerContribution><gtr:piContribution>Publication in Hepatology another two in progress.

MRC funded clinical training fellow</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Keystone Fibrosis meeting 2014 - postdoc</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A243DC4C-2500-42C1-8370-0F00C26601F5</gtr:id><gtr:impact>Talk to international audience and evening poster presented on same topic. Intense interest for discussions followed.

Scientific collaboration / interaction.</gtr:impact><gtr:outcomeId>54648c56cffcc7.53069494</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>North West regional Gastro. Conference 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC486F50-857A-4443-9A3D-407589ADA671</gtr:id><gtr:impact>Exciting discussions after talk and awarded best research paper presented.

Awarded prize for best research paper. Data in preparation for manuscript submission (Dec 2014).</gtr:impact><gtr:outcomeId>54648e516b57b2.65196239</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference (AASLD 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9982BB7B-956E-4044-A487-F4FD8E43E091</gtr:id><gtr:impact>AASLD conference, 9-13th November 2012, Boston, USA. 

Understanding the molecular mechanisms of liver fibrosis provides insight into novel biomarkers of disease.

Varinder Athwal, James Pritchett, Emma Harvey, Philip Ireland, Katherine Martin, Grace Dolman, William Irving, Neil Guha, Neil Hanley and Karen Piper Hanley.

Oral presentation of research at international conference.


Developing biomarkers for liver disease is an intense area f research and the talk will have been attended by key individuals across bot academia and industry at the forefront of developing these technologies. Our research will impact on this area.</gtr:impact><gtr:outcomeId>sUeL2VQjnbT</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.aasld.org</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keystone Fibrosis meeting 2014 - clinical fellow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>67128472-8F1C-4D50-B953-37355CA97DC0</gtr:id><gtr:impact>Intense discussions following talk and following the paper presented in evening poster session.

Collaborations and increased activity for follow-up discussions.</gtr:impact><gtr:outcomeId>54648ce32d8103.20695571</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>North West regional Gastro. Conference 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D419AD07-4F98-45C7-8748-4E67A4999D18</gtr:id><gtr:impact>Discussed broadly following talk - won prize for presentation.

Oral prize.</gtr:impact><gtr:outcomeId>54648de5a260d6.65306292</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab visit (University of Manchester)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5FB9881F-C042-4672-9877-669F99B2257A</gtr:id><gtr:impact>A level students from across the region invited to take part in a week long educational practical session on medical science. In addition given the opportunity to discuss careers with University based scientists with various backgrounds.

Annual event.</gtr:impact><gtr:outcomeId>WTB99bZS1aG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference (EASL oral-poster 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>43422A2B-4CF4-430B-ACB3-C85656BE166F</gtr:id><gtr:impact>This was a chosen abstract for a poster oral (and bursary award). There has been intense interest in this work following on from the presentation.

Intense interest in this piece of work - notable by additional talk invites and prizes.</gtr:impact><gtr:outcomeId>5464884fea5688.47224204</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference (poster AASLD 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8DC71817-C51C-4CC1-BC7D-FD356B69037B</gtr:id><gtr:impact>AASLD, 9-13th November 2012, Boston, USA.

Epimorphin signalling is associated with a quiescent-like HSC phenotype with implications for non invasive assay development in liver fibrosis

James Pritchett, Varinder S Athwal, Emma Harvey, Katherine Martin, Philip Ireland, Alexander Nicolaides, William L Irving, Indra N Guha, Neil A Hanley, Karen Piper Hanley

Significant interest in non invasive markers of disease with good attendance at poster.</gtr:impact><gtr:outcomeId>TCFWpRqvg78</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.aasld.org</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference (EASL poster 2013)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2D0339CD-EBFE-4D03-8B59-8043F02D485A</gtr:id><gtr:impact>EASL, 24-28th April 2013, Amsterdam.

Understanding integrin signalling during liver fibrosis provides insight into their modulation as a therapeutic strategy to treat the disease

Katherine Martin, James Pritchett, Emma Harvey, Varinder Athwal, Charles Streuli, Neil Hanley and Karen Piper Hanley

Poster presentation

significant interest in integrin signalling in liver disease.</gtr:impact><gtr:outcomeId>hRt5hRZNj6L</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.easl.eu</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Manchester)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>61CD5C75-7ACC-476D-924C-17CB4BCACC2E</gtr:id><gtr:impact>Researcher in residence - Scientific presentations and discussion to A level students to initiate interest in careers in the general area on science and technology. Also as general educational presentation.

This is an on-going annual event.</gtr:impact><gtr:outcomeId>ByiqV1cN9Ns</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>600CC27B-917E-418B-A3DF-048BE3332590</gtr:id><gtr:impact>A public event for adults and children with activities to engage the audience in basic science and technology. Allows hands on interaction and discussions with scientists.

Annual event</gtr:impact><gtr:outcomeId>LTZ76LQn5eh</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Manchester PhD MRC doctoral training account</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>594DCFAE-9149-4174-B615-F677C7306408</gtr:id><gtr:outcomeId>5464862fcf4e75.22186583</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Manchester PhD MRC doctoral training account</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F741CD68-7907-450A-9732-A2DA495EBD1E</gtr:id><gtr:outcomeId>r4aTieAyuHh</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellow</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C574984C-F846-419A-B5B5-A542532BEDBD</gtr:id><gtr:outcomeId>gKZJvzmqUXC</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to methods of predicting a subject's likelihood of developing
progressive fibrosis. The invention also relates to methods of selecting an appropriate
treatment regiment for the treatment of fibrosis in a subject. The invention also relates to a
method of treating progressive fibrosis in a subject.</gtr:description><gtr:grantRef>MR/J003352/1</gtr:grantRef><gtr:id>0F869125-1B94-4BCF-8F5F-513884F3BFF9</gtr:id><gtr:impact>A manuscript is i preparation for high impact publication.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54649101a7d537.03687230</gtr:outcomeId><gtr:patentId>Reference ICA/P207649GB (filed May 2014)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Prediction and treatment of progressive fibrosis</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to targeting of expression of the transcription factor SOX9 for treatment of conditions associated with aberrant expression of extracellular matrix (ECM) components resulting from up-regulation of SOX9 such as, for example, expression of collagens and other structural proteins resulting in liver fibrosis.</gtr:description><gtr:grantRef>MR/J003352/1</gtr:grantRef><gtr:id>4C6262CF-70B7-4493-AF4A-F528462F237A</gtr:id><gtr:impact>Additional publications PMID 22488688</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>bFVQP4QCEEh</gtr:outcomeId><gtr:patentId>GB0709506.0</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>SOX9 As Target For Fibrosis Therapy</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We have discovered a marker to predict individuals who will progress with fibrosis at an early stage of disease. This test has been investigated in one fibrotic aetiology to date and we are actively pursuing additional cohorts and diseases to test this in. Currently in close discussion with our IP department and have had market scoping exercise carried out. Looking at obtaining TSB funding either by generating a spin out company or through industrial partner.</gtr:description><gtr:id>395E8680-0526-41AC-8989-38001CB35536</gtr:id><gtr:impact>Patented technology and manuscript in preparation.
Potential for company spin-out or up-take from industry.</gtr:impact><gtr:outcomeId>546492e37930c3.07961872</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Prediction and treatment of progressive fibrosis</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1067CF81-D7B3-4AD9-B930-4EB75C5214E1</gtr:id><gtr:title>Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fcf6319aaaa051e71570ab1a5fbb0d4"><gtr:id>7fcf6319aaaa051e71570ab1a5fbb0d4</gtr:id><gtr:otherNames>Rowe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>i9Av75aTo5C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15E78F89-5DD1-4502-9AAA-852D819A9F54</gtr:id><gtr:title>Development of the human pancreas from foregut to endocrine commitment.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89d667e390777e96fcdb6fca0c79aac5"><gtr:id>89d667e390777e96fcdb6fca0c79aac5</gtr:id><gtr:otherNames>Jennings RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>nTwRnL7Ni3x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D89AEB35-02FB-4C84-8FC5-BE38EC4F4686</gtr:id><gtr:title>An integrative transcriptomic atlas of organogenesis in human embryos.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a9eddf48c28defea74e9aa5d5a375ae"><gtr:id>9a9eddf48c28defea74e9aa5d5a375ae</gtr:id><gtr:otherNames>Gerrard DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>585d6dcd24d121.75360845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0C7A12C-BD58-409B-B020-305DC6805404</gtr:id><gtr:title>Laser Capture and Deep Sequencing Reveals the Transcriptomic Programmes Regulating the Onset of Pancreas and Liver Differentiation in Human Embryos.</gtr:title><gtr:parentPublicationTitle>Stem cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89d667e390777e96fcdb6fca0c79aac5"><gtr:id>89d667e390777e96fcdb6fca0c79aac5</gtr:id><gtr:otherNames>Jennings RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-6711</gtr:issn><gtr:outcomeId>5a2fd8403cf606.29468178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D65F406-F165-4EDD-B772-8C19080AAA45</gtr:id><gtr:title>Spatiotemporal analysis of putative notochordal cell markers reveals CD24 and keratins 8, 18, and 19 as notochord-specific markers during early human intervertebral disc development.</gtr:title><gtr:parentPublicationTitle>Journal of orthopaedic research : official publication of the Orthopaedic Research Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dcdbdd4e3a7e3ab789a8bf3e8711399"><gtr:id>7dcdbdd4e3a7e3ab789a8bf3e8711399</gtr:id><gtr:otherNames>Rodrigues-Pinto R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0736-0266</gtr:issn><gtr:outcomeId>58c683066549f8.82040023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB521914-B462-418F-98FE-3302F03A1B65</gtr:id><gtr:title>PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f6c6d440adbbc77668a052f9c0d839"><gtr:id>55f6c6d440adbbc77668a052f9c0d839</gtr:id><gtr:otherNames>Martin K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>585d6dc9c43116.23302837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>827F319F-142E-4414-B01D-71F922A24106</gtr:id><gtr:title>SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis in mouse</gtr:title><gtr:parentPublicationTitle>Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6d5b12a38ada177266136b89e274ba4"><gtr:id>c6d5b12a38ada177266136b89e274ba4</gtr:id><gtr:otherNames>Athwal VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>54649847af4022.39349089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01CAA637-3423-496A-928C-C5E3AEA86089</gtr:id><gtr:title>Identification of a SOX9 extracellular matrix panel as novel biomarkers in liver fibrosis</gtr:title><gtr:parentPublicationTitle>Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/342a55fd73d4833f5182791e5a268b3b"><gtr:id>342a55fd73d4833f5182791e5a268b3b</gtr:id><gtr:otherNames>Varinder AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>PtEjg184Xvg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0A390A8-215C-4F8C-B2F9-3EB94DB7AB52</gtr:id><gtr:title>Integrins alpha-11 (ITGA11) and beta-1 (ITGB11) in myofibroblasts link P21-activated kinase (PAK) and Yes-associated protein (YAP) to hepatic fibrosis</gtr:title><gtr:parentPublicationTitle>Nature Communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f6c6d440adbbc77668a052f9c0d839"><gtr:id>55f6c6d440adbbc77668a052f9c0d839</gtr:id><gtr:otherNames>Martin K</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>546497d2938427.77245395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8952E19-1E8F-4866-B598-0F451EE2418D</gtr:id><gtr:title>Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8660600ed00a4ad9d4729870703f646"><gtr:id>f8660600ed00a4ad9d4729870703f646</gtr:id><gtr:otherNames>Pritchett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_14045_25_22488688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51C874B3-9429-4815-BE77-14AFA91ADAA8</gtr:id><gtr:title>Altered Phenotype of ?-Cells and Other Pancreatic Cell Lineages in Patients With Diffuse Congenital Hyperinsulinism in Infancy Caused by Mutations in the ATP-Sensitive K-Channel.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a777beff5e8bc97b71166359b79f13ff"><gtr:id>a777beff5e8bc97b71166359b79f13ff</gtr:id><gtr:otherNames>Salisbury RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>56dd882abd5b81.25855882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4B316CE-A02E-438C-9539-536C19AFC11D</gtr:id><gtr:title>Epimorphin alters the inhibitory effects of SOX9 on Mmp13 in activated hepatic stellate cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8660600ed00a4ad9d4729870703f646"><gtr:id>f8660600ed00a4ad9d4729870703f646</gtr:id><gtr:otherNames>Pritchett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e191e1919c1e32</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75390E5D-3048-4D01-A444-A9D0BD4D184D</gtr:id><gtr:title>SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6d5b12a38ada177266136b89e274ba4"><gtr:id>c6d5b12a38ada177266136b89e274ba4</gtr:id><gtr:otherNames>Athwal VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>5a2fd8a58eeff3.11458241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAF64193-36E3-4FDC-90C4-FDC2A3C4412D</gtr:id><gtr:title>The window period of NEUROGENIN3 during human gestation.</gtr:title><gtr:parentPublicationTitle>Islets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a777beff5e8bc97b71166359b79f13ff"><gtr:id>a777beff5e8bc97b71166359b79f13ff</gtr:id><gtr:otherNames>Salisbury RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1938-2014</gtr:issn><gtr:outcomeId>5464974c3682f2.02799126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08B7E97C-19CC-440B-9859-258B0C6DEC8B</gtr:id><gtr:title>Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86657e337abedb83adf26de5d8f16dcd"><gtr:id>86657e337abedb83adf26de5d8f16dcd</gtr:id><gtr:otherNames>Baxter M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56dd8861ccfa76.33118476</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J003352/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>